

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* <u>ARCH Venture Partners IX, LLC</u>			2. Issuer Name and Ticker or Trading Symbol <u>Lyell Immunopharma, Inc. [LYEL]</u>			5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) _____ Other (specify below) _____		
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) <u>06/21/2021</u>			6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person		
8755 W. HIGGINS ROAD SUITE 1025			4. If Amendment, Date of Original Filed (Month/Day/Year)					
(Street) <u>CHICAGO IL 60631</u>								
(City) (State) (Zip)								

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	06/21/2021		C		18,206,358	A	(1)	18,206,358	I	ARCH Venture Fund IX, L.P. ⁽²⁾
Common Stock	06/21/2021		C		18,206,358	A	(1)	18,206,358	I	ARCH Venture Fund IX Overage, L.P. ⁽²⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Series A Convertible Preferred Stock	(1)	06/21/2021		C		17,771,216		(1)	(1)	Common Stock	17,771,216	\$0.00	0	I	ARCH Venture Fund IX, L.P. ⁽²⁾
Series A Convertible Preferred Stock	(1)	06/21/2021		C		17,771,216		(1)	(1)	Common Stock	17,771,216	\$0.00	0	I	ARCH Venture Fund IX Overage, L.P. ⁽²⁾
series C Convertible Preferred Stock	(1)	06/21/2021		C		435,142		(1)	(1)	Common Stock	435,142	\$0.00	0	I	ARCH Venture Fund IX, L.P. ⁽²⁾
Series C Convertible Preferred Stock	(1)	06/21/2021		C		435,142		(1)	(1)	Common Stock	435,142	\$0.00	0	I	ARCH Venture Fund IX Overage, L.P. ⁽²⁾

1. Name and Address of Reporting Person*
ARCH Venture Partners IX, LLC

(Last) (First) (Middle)
8755 W. HIGGINS ROAD
SUITE 1025

(Street)
CHICAGO IL 60631

(City) (State) (Zip)

1. Name and Address of Reporting Person*
ARCH Venture Fund IX Overage, L.P.

(Last) (First) (Middle)
8755 W. HIGGINS ROAD

SUITE 1025

(Street)

CHICAGO IL 60631

(City)

(State)

(Zip)

1. Name and Address of Reporting Person*

[ARCH Venture Fund IX, L.P.](#)

(Last)

(First)

(Middle)

8755 W. HIGGINS ROAD
SUITE 1025

(Street)

CHICAGO IL 60631

(City)

(State)

(Zip)

1. Name and Address of Reporting Person*

[ARCH Venture Partners IX Overage, L.P.](#)

(Last)

(First)

(Middle)

8755 W. HIGGINS ROAD
SUITE 1025

(Street)

CHICAGO IL 60631

(City)

(State)

(Zip)

1. Name and Address of Reporting Person*

[ARCH Venture Partners IX, L.P.](#)

(Last)

(First)

(Middle)

8755 W. HIGGINS ROAD
SUITE 1025

(Street)

CHICAGO IL 60631

(City)

(State)

(Zip)

1. Name and Address of Reporting Person*

[CRANDELL KEITH](#)

(Last)

(First)

(Middle)

8755 W. HIGGINS ROAD
SUITE 1025

(Street)

CHICAGO IL 60631

(City)

(State)

(Zip)

1. Name and Address of Reporting Person*

[BYBEE CLINTON](#)

(Last)

(First)

(Middle)

8755 W. HIGGINS ROAD
SUITE 1025

(Street)

CHICAGO IL 60631

(City)

(State)

(Zip)

Explanation of Responses:

1. The Issuer's Series A Convertible Preferred Stock and Series C Convertible Preferred Stock converted into Common Stock on a 1-for-1 basis and had no expiration date.

2. ARCH Venture Partners IX, L.P. (AVP IX LP) is the sole general partner of ARCH Venture Fund IX, L.P. (ARCH IX). ARCH Venture Partners IX Overage, L.P. (AVP IX Overage LP) is the sole general partner of ARCH Venture Fund IX Overage, L.P. (ARCH IX Overage). ARCH Venture Partners IX, LLC (AVP IX LLC) is the sole general partner of each of AVP IX LP and AVP IX Overage LP. Keith Crandell and Clinton Bybee are managing directors of AVP IX LLC (the AVP IX MDs). AVP IX LP and AVP IX Overage LP may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, respectively. AVP IX LLC may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, and each of the AVP IX MDs may be deemed to share the power to direct the disposition and vote of the shares held by ARCH IX and ARCH IX Overage. AVP IX LP, AVP IX Overage LP, AVP IX LLC, and the AVP IX MDs each disclaim beneficial ownership except to the extent of any pecuniary interest therein.

Remarks:

[/s/ ARCH Venture Fund IX, L.P., 06/21/2021](#)

[By: ARCH Venture Partners IX,](#)

[L.P., its General Partner, By:](#)

[ARCH Venture Partners IX,](#)

<u>LLC, its General Partner, By: Mark McDonnell, attorney in-fact</u>	
<u>/s/ ARCH Venture Fund IX Overage, L.P., By: ARCH Venture Partners IX Overage, L.P., its General Partner, By: ARCH Venture Partners IX, LLC, its General Partner, By: Mark McDonnell, attorney in-fact</u>	<u>06/21/2021</u>
<u>/s/ ARCH Venture Partners IX, L.P., By: ARCH Venture Partners IX, LLC, its General Partner, By: Mark McDonnell, attorney in-fact</u>	<u>06/21/2021</u>
<u>/s/ ARCH Venture Partners IX Overage, L.P., By: ARCH Venture Partners IX, LLC, its General Partner, By: Mark McDonnell, attorney in-fact</u>	<u>06/21/2021</u>
<u>/s/ ARCH Venture Partners IX, LLC, By: Mark McDonnell, attorney in-fact</u>	<u>06/21/2021</u>
<u>/s/ Keith Crandell, By: Mark McDonnell, attorney in-fact</u>	<u>06/21/2021</u>
<u>/s/ Clinton Bybee, By: Mark McDonnell, attorney in-fact</u>	<u>06/21/2021</u>
** Signature of Reporting Person	Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.